Bausch + Lomb (BLCO) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Bausch + Lomb reported $1.28 billion in revenue for Q4 2024, a year-over-year increase of 9.1% and a surprise of +1.17% over the Zacks Consensus Estimate of $1.27 billion [1] - The company's EPS for the same period was $0.25, compared to $0.24 a year ago, resulting in an EPS surprise of +4.17% [1] Revenue Breakdown - Vision Care revenues reached $723 million, exceeding the estimated $708.34 million, reflecting a +9.2% change year-over-year [4] - Pharmaceuticals revenues were reported at $326 million, slightly below the estimated $335.50 million, with a year-over-year increase of +6.2% [4] - Product sales totaled $1.28 billion, surpassing the average estimate of $1.26 billion, marking a +9.2% year-over-year change [4] - Surgical revenues amounted to $231 million, exceeding the average estimate of $215.26 million, representing a +13.2% year-over-year increase [4] - Other revenues were reported at $5 million, matching the two-analyst average estimate, with no year-over-year change [4] Stock Performance - Bausch + Lomb shares have returned -4.8% over the past month, contrasting with the Zacks S&P 500 composite's +4.7% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]